Effects of endothelin receptors ETA and ETB blockade on renal haemodynamics in normal rats and in rats with experimental congestive heart failure

2002 ◽  
Vol 103 (s2002) ◽  
pp. 245S-248S ◽  
Author(s):  
Zaid ABASSI ◽  
Bahaa FRANCIS ◽  
Jerry WESSALE ◽  
Elena OVCHARENKO ◽  
Joseph WINAVER ◽  
...  

The present study examined the effects of two highly selective endothelin-1 (ET-1) receptor antagonists, ABT-627 (ETA blocker) and A-192621 (ETB blocker), on the systemic and renal haemodynamic effects of ET-1 in normal rats and in rats with experimental congestive heart failure (CHF) produced by aortocaval fistula. Intravenous injection of ET-1 (1.0nmol·kg-1 of body weight) to anaesthetized normal rats produced sustained decreases in renal blood flow (RBF) (assessed by ultrasonic flowmetry) and glomerular filtration rate (GFR), and significant increases in renal vascular resistance (RVR) and mean arterial pressure (MAP). Pretreatment with ABT-627 (1mg·h-1·kg-1 of body weight) abolished the pressor response to ET-1 without affecting the depressor phase, and significantly impaired the renal vasoconstriction. The systemic and renal vasoconstrictive effects of ET-1 in normal rats were significantly augmented by pretreatment with 3.0mg·h-1·kg-1 of A-192621. Baseline RBF and GFR in rats with CHF were reduced significantly compared with control rats, whereas RVR was elevated. The hypertensive effect of ET-1 was attenuated in rats with CHF. In the presence of ETA blockade, the pressor response to ET-1 was completely abolished in CHF rats. Furthermore, pretreatment with ABT-627 enhanced the recovery from ET-1- dependent vasoconstriction and remarkably reversed the ET-1-induced hypofiltration. Blockade of ETB receptors in rats with CHF further exposed the exaggerated ET-1-induced renal vasoconstriction. Our data demonstrate that experimental CHF is associated with altered responsiveness to ETA- and ETB-mediated systemic and renal effects of ET-1. Furthermore, in CHF, as in control rats, the ETB-mediated vasodilatory response may serve as an important compensatory counterbalance to the adverse ETA-mediated effects.

2001 ◽  
Vol 49 (10) ◽  
pp. 1293-1300 ◽  
Author(s):  
Gad M. Bialik ◽  
Zaid A. Abassi ◽  
Ilan Hammel ◽  
Joseph Winaver ◽  
Dina Lewinson

The natriuretic peptides are believed to play an important role in the pathophysiology of congestive heart failure (CHF). We utilized a quantitative cytomorphometric method, using double immunocytochemical labeling, to assess the characteristics of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in atrial granules in an experimental model of rats with CHF induced by aortocaval fistula. Rats with CHF were further divided into decompensated (sodium-retaining) and compensated (sodium-excreting) subgroups and compared with a sham-operated control group. A total of 947 granules in myocytes in the right atrium were analyzed, using electron microscopy and a computerized analysis system. Decompensated CHF was associated with alterations in the modal nature of granule content packing, as depicted by moving bin analysis, and in the granule density of both peptides. In control rats, the mean density of gold particles attached to both peptides was 347.0 ± 103.6 and 306.3 ± 89.9 gold particles/μm2 for ANP and BNP, respectively. Similar mean density was revealed in the compensated rats (390.6 ± 81.0 and 351.3 ± 62.1 gold particles/μm2 for ANP and BNP, respectively). However, in rats with decompensated CHF, a significant decrease in the mean density of gold particles was observed (141.6 ± 67.3 and 158.0 ± 71.2 gold particles/μm2 for ANP and BNP, respectively; p < 0.05 compared with compensated rats, for both ANP and BNP). The ANP:BNP ratio did not differ between groups. These findings indicate that the development of decompensated CHF in rats with aortocaval fistula is associated with a marked decrease in the density of both peptides in atrial granules, as well as in alterations in the quantal nature of granule formation. The data further suggest that both peptides, ANP and BNP, may be regulated in the atrium by a common secretory mechanism in CHF.


Drugs ◽  
1987 ◽  
Vol 34 (Supplement 3) ◽  
pp. 81-84 ◽  
Author(s):  
P. Held ◽  
K. Swedberg

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Vesna Ristovska

Abstract Background and Aims The advanced congestive heart failure (CHF), may provoke functional kidney disturbances with insufficient and resistant to conservative therapy water excretion. The treatment of the chronic renal failure (CRF) with active dialysis related to ultrafiltration (UF), may overcome the renal diuretics resistance with diuresis restoration and oedema elimination. The aim of the study was to define the indications for active, discontinued UF in setting of the CHF refractory to drugs, especially in the treatment of oedema. Method We investigated 12 patients, mean age 62,4+/-5,3 years, with incipient renal failure, but advanced congestive heart failure. Seven of them were males and 5 females. The indication for discontinued UF, was the severe expressed heart failure, reduced diuresis and initial renal insufficiency. In all investigated patients, before and after each UF procedure, the serum sodium and potassium, blood urea nitrogen (BUN), creatinin and osmolality were detected. The body weight, abdominal and crural parameters were noted before and after dialysis. Results The recovery was achieved in 10 patients with CHF, but 2 patients out of 12 have not demonstrated satisfactory response to UF. The biochemical features encountered to CHF patients suggest chronic hyponatriemia, hypokalemia and hypovolemia. Proteinuria range 1,2 to 3,6 g/l, was present in 6 patients. The clinical data were performed with oedema formation, reduced diuresis and dispnea. Mean UF rate achieved after several dialysis was 12,4+/- 7,6, lit. Conclusion Chronic heart failure in chronic renal patients, with severe oedemas is an indication for UF therapy, even if the values of BUN and creatinin are not increased. Reduction of the body weight and the extracellular volume, contribute for improved survival in these patients. However the risk of complications is high and not always with successful treatment.


Heart ◽  
1981 ◽  
Vol 46 (5) ◽  
pp. 528-530 ◽  
Author(s):  
H Ikram ◽  
A H Maslowski ◽  
M G Nicholls

1980 ◽  
Vol 2 ◽  
pp. S427-S441 ◽  
Author(s):  
K. H. Kuck ◽  
P. Hanrath ◽  
A. Zenke ◽  
D. Mathey ◽  
W. Bleifeld

Heart ◽  
1997 ◽  
Vol 78 (5) ◽  
pp. 444-449 ◽  
Author(s):  
M. L Kukin ◽  
J. Kalman ◽  
M. M Mannino ◽  
C. Buchholz-Varley ◽  
O. Ocampo

2001 ◽  
Vol 7 (1) ◽  
pp. 38-44 ◽  
Author(s):  
Motoyuki Nakamura ◽  
Naoshi Arakawa ◽  
Hiroaki Yoshida ◽  
Seiichi Saitoh ◽  
Hisashi Kon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document